ISA 2022 – Alnylam takes heart from full Apollo-B data
But it is still unclear how much of a threat Onpattro will be to Pfizer’s Vyndaqel.
Brace for an end-of-year boost to drug approvals
The first half of 2022 was slow on the regulatory front, but plenty of big decisions remain for Bristol Myers Squibb, Apellis and others.
Novo’s cardiovascular and rare disease charge continues
Before the Forma deal Novo brought in assets via Corvidia, Prothena and Heartseed. Some have progressed faster than others.
Alnylam’s heart beats stronger
A win in Apollo-B should open up the multi-billion cardiomyopathy market, but questions remain.
Biotech’s important data reveals
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
